Cogent Biosciences, Inc. key statistics and ratios

In fiscal 2020, Cogent Biosciences, Inc. had return on equity of -56.2%, an operating margin of -1044.3%, debt equal to 0.0% of equity and a current ratio of 18.70. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cogent Biosciences, Inc.: financial ratios, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020
Operating margin	−312.8%	−369.9%	−143.0%	<−999%
Net margin	−304.9%	−354.8%	−141.5%	−950.4%
Free-cash-flow margin	−319.9%	−339.4%	−184.7%	—
Return on equity	—	—	−69.2%	−56.2%
Return on assets	−51.9%	−51.1%	−47.0%	−49.8%
Asset turnover	0.17	0.14	0.33	0.05
Current ratio	3.79	3.25	3.06	18.70
Debt to equity	—	0.0%	0.0%	0.0%
R&D as % of revenue	356.8%	393.3%	194.3%	327.0%
Capital spending as % of revenue	10.9%	5.6%	0.1%	—

US$ thousands unless shown otherwise. Fiscal quarters.

Cogent Biosciences, Inc.: financial ratios, quarterly
Quarter	2019 Q1Mar 2019	2019 Q2Jun 2019	2019 Q3Sept 2019	2019 Q4Dec 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020
Operating margin	−387.8%	−335.9%	<−999%	14.7%	−87.3%	<−999%	<−999%	—
Net margin	−382.9%	−335.1%	<−999%	15.0%	−86.7%	<−999%	<−999%	—
Free-cash-flow margin	−378.6%	−361.5%	−998.5%	−55.3%	—	—	—	—
Current ratio	2.65	2.41	1.96	3.06	3.37	2.90	6.63	18.70
R&D as % of revenue	406.3%	338.3%	>999%	67.7%	135.1%	971.4%	>999%	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cogent Biosciences, Inc.